RecruitingPhase 2NCT06508099

Vitamin A and D Supplementation in Allogeneic HCT

Randomized Study of Vitamin A and D Prophylaxis Before Allogeneic Related and Unrelated Hematopoietic Stem Cell Transplantation


Sponsor

St. Petersburg State Pavlov Medical University

Enrollment

220 participants

Start Date

May 15, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The therapy under investigation is the addition of 300 000 IU of vitamin A and 100 000 IU of vitamin D before conditioning. The study will include patients with malignant diseases in hematologic response with indications for allogeneic transplantation with matched related or matched unrelated donor.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at whether giving Vitamin A and Vitamin D supplements to patients undergoing a donor stem cell transplant (allogeneic HCT) for blood cancers can reduce complications and improve outcomes after the procedure. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with a blood cancer such as leukemia (AML or ALL), myelodysplastic syndrome, chronic myeloid leukemia, lymphoma, or myeloma - Your disease is in remission or at least partial response before the transplant - You have a compatible donor (fully matched related donor, or 9–10 out of 10 matched unrelated donor) - You do not have other serious health conditions that would prevent the transplant **You may NOT be eligible if...** - Your disease is not in adequate remission before transplant - You do not have a compatible donor - You have serious other illnesses that could interfere with the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVitamin A

300 000 IU single dose orally

DRUGVitamin D3

100 000 IU single dose orally


Locations(1)

RM Gorbacheva Research Institute

Saint Petersburg, Russia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06508099


Related Trials